Roche signs a licensing agreement with Shanghai-based Rona Therapeutics for an RNA interference (RNAi) obesity therapy targeting fat tissue. Under the deal, Roche is reported to pay as much as $100 million upfront, with the total contract value reaching up to about $1.16 billion depending on further terms and milestones.
Outlets also frame the transaction as part of Roche’s broader push to expand its pipeline in weight-management and metabolic medicines. Quartz and BioPharma Dive both highlight that the therapy is aimed at reducing visceral fat, and they describe the agreement as adding to Roche’s recent activity in China-linked partnerships. The coverage emphasizes the deal’s size and structure, with differences mainly in how each outlet characterizes the context of Roche’s strategy and the specific focus on fat types rather than on the core commercial terms.
